| A | B |
|---|
| Authorization | Procss of determining that a prescription can be filled |
| Consent | Agreement to participate |
| Contraception Barrier | Diaphragm, latex condoms, cervical cap with spermicide, vaginal sponge |
| Contraception Primary | Tubal ligation, partner’s vasectomy, intrauterine device, birth control pills, topical/injectable/implantable/insertable hormonal birth control products |
| Counsel | Education, advice and guidance on the use of isotretinoin |
| Delegate Prescriber | An alternate Prescriber assigned by the Primary Prescriber to care for the Patient. |
| Distributor | An entity similar in function to Wholesaler |
| Female of Child Bearing Potential (FCBP) | A non-menopausal female who has not had a hysterectomy, bilateral oophorectomy, or documented ovarian failure. |
| Impersonation | The process of allowing the Call Center Operator to complete the IVR/Web transactions for a User |
| Medically confirmed Pregnancy | A pregnancy report supported by a laboratory test result and/or Prescriber attestation |
| Non-Female of Child Bearing Potential (NFCBP) | A male or a female who does not meet the criteria for a FCBP including postmenopausal females and women who have had a hysterectomy |
| Designee (Office Staff) | A member of a Prescribers office staff that will be authorized to perform certain Prescriber activities |
| Registered Users | A Prescriber, Pharmacy or Patient that is registered in the program |
| Risk Managemetn Authorization (RMA) Code | A code that will be presented by the system to the Pharmacist upon receiving authorization to dispense a prescription. |
| Warm Transfer | Transferring a phone call from one person to another, assuring that the caller is connected to the new contact prior to the original call recipient leaving the call |
| Wet Signature | Signature placed on a document (specifically the Registration |
| Birth Defect | A congenital defect |
| Kendle Pregnancy Registry | Confidential registry to collect data from FCBPs who become pregnant during treatment or for 30 days after stopping isotretinoin |
| Infant Exposure | Exposure of the infant through the mother during treatment by breast feeding |
| In House Pregnancy Test | Non-laboratory based pregnancy test, usually conducted in the Prescriber’s office |
